Arca
Skip to content
Tools
Tools

Tubulin

Complex group in Homo sapiens that 80 drugs act on.

  • Drugs that act on it: 80
  • Approved: 17
  • In phases 1 to 3: 63
  • Sponsors: 38
  • Genes: 15

Who is on it, and how far along

Every drug ChEMBL records acting on TUBA1A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 30
  • Antibody-drug conjugate 35
  • Protein or peptide 3
  • Other 12

Approved17

Phase 312

Phase 239

Phase 112

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 67 of 80 act as: Tubulin inhibitor; the rest name their own mechanism.
PaclitaxelBoxed warningApprovedHQ Specialty PharmaSmall moleculeInhibitor1,898
Docetaxel anhydrousBoxed warningApprovedMerck & Co. (MSD)Small moleculeInhibitor664
VincristineBoxed warningApprovedEli LillySmall moleculeInhibitor353
VinorelbineBoxed warningApprovedPierre FabreSmall moleculeInhibitor102
Enfortumab vedotinBoxed warningApprovedAstellas PharmaAntibody-drug conjugateInhibitor94
ColchicineApprovedAR HoldingSmall moleculeInhibitor87
EribulinApprovedEisaiSmall moleculeInhibitor84
Polatuzumab vedotinApprovedRocheAntibody-drug conjugateInhibitor83
Trastuzumab emtansineBoxed warningApprovedGeneQuantum Healthcare (Suzhou) Co., Ltd.Antibody-drug conjugateInhibitor76
Brentuximab vedotinBoxed warningApprovedPfizerAntibody-drug conjugateInhibitor58
VinblastineApprovedEli LillySmall moleculeInhibitor53
Belantamab mafodotinWithdrawn Boxed warningApprovedGSKAntibody-drug conjugateInhibitor47
CabazitaxelBoxed warningApprovedSanofiSmall moleculeInhibitor27
Mirvetuximab soravtansineBoxed warningApprovedAbbVieAntibody-drug conjugateInhibitor21
Tisotumab vedotinBoxed warningApprovedPfizerAntibody-drug conjugateInhibitor4
IxabepiloneBoxed warningApprovedR-Pharm USSmall moleculeInhibitor3
VinflunineApprovedMerck & Co. (MSD)Small moleculeInhibitor2
Disitamab vedotinPhase 3RemeGen Co., Ltd.Antibody-drug conjugateDisrupting agentTubulin disrupting agent90
Telisotuzumab vedotinPhase 3AbbVieAntibody-drug conjugateInhibitor5
PlinabulinPhase 3BeyondSpring Pharmaceuticals Inc.Small moleculeInhibitor4
PatupilonePhase 3Novartis PharmaceuticalsSmall moleculeStabiliserTubulin stabiliser3
Paclitaxel docosahexaenoic acidPhase 3Daiichi SankyoSmall moleculeStabiliserTubulin stabiliser1
ANG1005Phase 3Angiochem IncProtein or peptideInhibitor0
Depatuxizumab mafodotinPhase 3AbbVieAntibody-drug conjugateInhibitor0
FosbretabulinPhase 3Mateon TherapeuticsSmall moleculeInhibitor0
LarotaxelPhase 3SanofiSmall moleculeStabiliserTubulin stabiliser0
OmbrabulinPhase 3SanofiSmall moleculeInhibitor0
Paclitaxel poliglumexPhase 3Cti BiopharmaSmall moleculeStabiliserTubulin stabiliser0
Tusamitamab ravtansinePhase 3SanofiAntibody-drug conjugateInhibitor0
Anetumab ravtansinePhase 2BayerAntibody-drug conjugateInhibitor3
Anvatabart opadotinPhase 2Zhejiang Medicine Co., Ltd.Antibody-drug conjugateInhibitor1
Ladiratuzumab vedotinPhase 2RocheAntibody-drug conjugateInhibitor1
AGS-16C3FPhase 2Agensys, Inc.OtherDisrupting agentTubulin disrupting agent0
Azintuxizumab vedotinPhase 2AbbVieAntibody-drug conjugateInhibitor0
BMS-275183Phase 2Bristol-Myers SquibbSmall moleculeStabiliserTubulin stabiliser0
Cantuzumab mertansinePhase 2—Antibody-drug conjugateInhibitor0
Cantuzumab ravtansinePhase 2AbbVieAntibody-drug conjugateInhibitor0
Coltuximab ravtansinePhase 2SanofiAntibody-drug conjugateInhibitor0
CrolibulinPhase 2EpiCept CorporationSmall moleculeInhibitor0
DavunetidePhase 2Allon TherapeuticsProtein or peptideStabiliserTubulin stabiliser0
Denintuzumab mafodotinPhase 2PfizerAntibody-drug conjugateInhibitor0
Dolastatin-10Phase 2—Small moleculeInhibitor0
Enapotamab vedotinPhase 2—Antibody-drug conjugateInhibitor0
Epothilone dPhase 2Bristol-Myers SquibbSmall moleculeStabiliserTubulin stabiliser0
Glembatumumab vedotinPhase 2Celldex TherapeuticsAntibody-drug conjugateInhibitor0
Indatuximab ravtansinePhase 2BiotestAntibody-drug conjugateInhibitor0
IndibulinPhase 2Alaunos TherapeuticsSmall moleculeInhibitor0
Indusatumab vedotinPhase 2Takeda Pharmaceuticals USAAntibody-drug conjugateInhibitor0
KOS-1584Phase 2Bristol-Myers SquibbSmall moleculeStabiliserTubulin stabiliser0
LexibulinPhase 2Gilead SciencesSmall moleculeInhibitor0
Lifastuzumab vedotinPhase 2RocheAntibody-drug conjugateInhibitor0
Lorvotuzumab mertansinePhase 2AbbVieAntibody-drug conjugateInhibitor0
Losatuxizumab vedotinPhase 2—Antibody-drug conjugateInhibitor0
Mecbotamab vedotinPhase 2—Antibody-drug conjugateInhibitor0
MilataxelPhase 2Wyeth is now a wholly owned subsidiary of PfizerSmall moleculeInhibitor0
Pinatuzumab vedotinPhase 2RocheAntibody-drug conjugateInhibitor0
PlocabulinPhase 2PharmaMarSmall moleculeInhibitor0
Praluzatamab ravtansinePhase 2CytomX TherapeuticsAntibody-drug conjugateInhibitor0
SagopilonePhase 2BayerSmall moleculeStabiliserTubulin stabiliser0
SAR-566658Phase 2SanofiOtherInhibitor0
SoblidotinPhase 2Daiichi SankyoSmall moleculeInhibitor0
Sofituzumab vedotinPhase 2RocheAntibody-drug conjugateInhibitor0
T-900607Phase 2TularikSmall moleculeDisrupting agentTubulin disrupting agent0
TasidotinPhase 2SanofiProtein or peptideInhibitor0
Trastuzumab botidotinPhase 2—Antibody-drug conjugateInhibitor0
Vandortuzumab vedotinPhase 2RocheAntibody-drug conjugateInhibitor0
VerubulinPhase 2Myrexis Inc.Small moleculeDisrupting agentTubulin disrupting agent0
Vorsetuzumab mafodotinPhase 2PfizerAntibody-drug conjugateInhibitor0
Aprutumab ixadotinPhase 1BayerAntibody-drug conjugateInhibitor0
ASG-5MEPhase 1Astellas PharmaOtherInhibitor0
AVE-9633Phase 1SanofiOtherInhibitor0
BIIB-015Phase 1BiogenOtherInhibitor0
Bivatuzumab mertansinePhase 1—Antibody-drug conjugateInhibitor0
IMGN-388Phase 1AbbVieOtherInhibitor0
MLN-2704Phase 1Takeda Pharmaceuticals USAOtherInhibitor0
PF-06263507Phase 1—OtherInhibitor0
RG-7598Phase 1—OtherInhibitor0
RG-7600Phase 1—OtherInhibitor0
RG-7636Phase 1—OtherInhibitor0
RG-7841Phase 1RocheOtherInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 135 in all, from ClinicalTrials.gov.
ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast CancerDocetaxel anhydrousPhase 2Not yet recruitingJin Sun BitarNov 20, 2026
Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III TrialPaclitaxelPhase 3Not yet recruitingXuekui LiuNov 19, 2026
ASTAR: Sacituzumab Govitecan For Breast CancerDocetaxel anhydrousPhase 2Not yet recruitingMassachusetts General HospitalNov 19, 2026
Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung CancerPaclitaxelPhase 3Not yet recruitingGoethe UniversityNov 17, 2026
Iparomlimab and Tuvonralimab Injection (QL1706)Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic CancerPaclitaxelPhase 2Active, not recruitingTongji HospitalNov 16, 2026
A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal MelanomaPaclitaxelPhase 2RecruitingSun Yat-sen UniversityNov 13, 2026
Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung CancerPaclitaxelPhase 2Not yet recruitingGuizhou Medical UniversityNov 13, 2026
AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRPColchicineNot applicableRecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNov 12, 2026
MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerMirvetuximab soravtansinePhase 2Not yet recruitingTongji HospitalNov 12, 2026
PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian CancerPaclitaxel, Docetaxel anhydrousPhase 2Not yet recruitingShanghai Gynecologic Oncology GroupNov 12, 2026
RELEASE Ph2 RT-310 BPH StudyPaclitaxelPhase 2Not yet recruitingResurge Therapeutics Inc.Nov 10, 2026
A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic CancerPaclitaxelNot applicableNot yet recruitingRuijin HospitalNov 10, 2026
Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast CancerDocetaxel anhydrous—Active, not recruitingPeking Union Medical College HospitalNov 9, 2026
Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line ImmunotherapyDocetaxel anhydrousPhase 2RecruitingAnhui Provincial HospitalNov 9, 2026
QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II StudyVincristinePhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNov 6, 2026
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLVincristineNot applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNov 6, 2026
Hs-CRP-Guided Colchicine Treatment Targets in Very-High-Risk Patients With Coronary Artery Disease After PCI (TARGET-CHD)ColchicineNot applicableNot yet recruitingSir Run Run Shaw HospitalNov 5, 2026
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Polatuzumab vedotinPhase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLCNov 5, 2026
Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaPolatuzumab vedotinPhase 2Not yet recruitingM.D. Anderson Cancer CenterNov 5, 2026
A Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter TransformationVincristinePhase 2RecruitingGerman CLL Study GroupNov 5, 2026
Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaVincristinePhase 1Not yet recruitingCity of Hope Medical CenterNov 3, 2026
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerEnfortumab vedotinPhase 2RecruitingFox Chase Cancer CenterNov 2, 2026
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialPolatuzumab vedotinPhase 2Not yet recruitingUniversity of WashingtonNov 2, 2026
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Polatuzumab vedotin, VincristinePhase 3Not yet recruitingAstraZenecaNov 2, 2026
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective StudyPolatuzumab vedotinPhase 4RecruitingThe First Hospital of Jilin UniversityNov 2, 2026
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Docetaxel anhydrousPhase 1 / Phase 2Not yet recruitingMerck Sharp & Dohme LLCNov 2, 2026
Colchicine in Pulmonary Artery Hypertension PatientsColchicinePhase 2Not yet recruitingAin Shams UniversityOct 30, 2026
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast CancerVinorelbinePhase 2Not yet recruitingYunnan Cancer HospitalOct 30, 2026
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate CancerDocetaxel anhydrousPhase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOct 30, 2026
Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction AdenocarcinomaDocetaxel anhydrousPhase 2Not yet recruitingFujian Cancer HospitalOct 29, 2026
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal CancerMirvetuximab soravtansine—RecruitingAbbVieOct 27, 2026
Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerVinorelbineEarly phase 1RecruitingOliver JonasOct 23, 2026
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]Enfortumab vedotinPhase 1 / Phase 2RecruitingDaiichi SankyoOct 22, 2026
Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene AbnormalitiesVincristinePhase 1RecruitingBeijing Tongren HospitalOct 22, 2026
Randomized Interventional Clinical Trial on the Prevention of Atrial Fibrillation Using Colchicine, Amiodarone And a Posterior Pericardiotomy.ColchicinePhase 3Not yet recruitingElsanOct 21, 2026
Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasPolatuzumab vedotinPhase 2RecruitingNational Research Center for Hematology, RussiaOct 20, 2026
Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean FeverColchicinePhase 3Not yet recruitingR-PharmOct 19, 2026
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast CancerEribulinPhase 3Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Oct 19, 2026
Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerDisitamab vedotinPhase 2Not yet recruitingTianjin Medical University Second HospitalOct 16, 2026
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial CarcinomaEnfortumab vedotin—RecruitingComprehensive Cancer Center Munich (CCCM)Oct 13, 2026
Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaEnfortumab vedotinPhase 2Not yet recruitingNorthwestern UniversityOct 7, 2026
A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After RadiotherapyColchicinePhase 2Not yet recruitingM.D. Anderson Cancer CenterOct 5, 2026
Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)Enfortumab vedotin—RecruitingLMU KlinikumOct 2, 2026
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerTrastuzumab emtansine—RecruitingFundación Santa Fe de BogotaOct 2, 2026
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerCabazitaxelPhase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research GroupOct 1, 2026
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder CancerDisitamab vedotinPhase 1Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOct 1, 2026
The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.Belantamab mafodotinPhase 2Not yet recruitingMedical Association for the Study of Cancer Biology and TreatmentSep 28, 2026
Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 DiabetesColchicinePhase 2RecruitingTan Tock Seng HospitalSep 24, 2026
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Belantamab mafodotinPhase 1Not yet recruitingCanadian Myeloma Research GroupSep 21, 2026
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerEnfortumab vedotin, Mirvetuximab soravtansine, Trastuzumab emtansinePhase 2Not yet recruitingFudan UniversitySep 17, 2026
A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsEribulin, VinorelbinePhase 2Not yet recruitingShanghai Henlius BiotechSep 17, 2026
A Phase 3 Trial in Advanced Epithelioid MesotheliomaVinorelbinePhase 3Not yet recruitingVivace Therapeutics, IncSep 17, 2026
A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerEnfortumab vedotinPhase 2Not yet recruitingUniversity of UtahSep 16, 2026
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaVincristinePhase 1 / Phase 2Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.Sep 14, 2026
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaEnfortumab vedotinPhase 2 / Phase 3RecruitingSummit TherapeuticsSep 11, 2026
Colchicine Effect on Amyotrophic Lateral Sclerosis PatientsColchicinePhase 2Not yet recruitingAzienda Ospedaliero-Universitaria di ModenaSep 10, 2026
A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersEribulinPhase 1 / Phase 2Not yet recruitingAdvenchen Pharmaceuticals, LLC.Sep 10, 2026
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS InvolvementPolatuzumab vedotin, VincristinePhase 2Not yet recruitingPengpeng XuSep 10, 2026
A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG FailureDisitamab vedotinPhase 1Not yet recruitingXiangya Hospital of Central South UniversityAug 25, 2026
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCLPolatuzumab vedotinNot applicableRecruitingThe First Affiliated Hospital of Xiamen UniversityAug 21, 2026
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder CancerDisitamab vedotinPhase 2 / Phase 3Not yet recruitingTianjin Medical University Second HospitalAug 10, 2026
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Belantamab mafodotinPhase 2Not yet recruitingPolish Myeloma ConsortiumAug 6, 2026
Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerMirvetuximab soravtansinePhase 2Not yet recruitingPeking University Third HospitalAug 3, 2026
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland CarcinomaDisitamab vedotinPhase 2Not yet recruitingWest China HospitalAug 3, 2026
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Belantamab mafodotinPhase 1Not yet recruitingMontefiore Medical CenterJul 22, 2026
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )Disitamab vedotinPhase 2Not yet recruitingPeking University First HospitalJul 22, 2026
Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)Brentuximab vedotinPhase 2Not yet recruitingPeking University First HospitalJul 21, 2026
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerDisitamab vedotinPhase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJul 21, 2026
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBCDisitamab vedotinPhase 3RecruitingZhiquan HuJul 9, 2026
A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α(FRα)Mirvetuximab soravtansine—Not yet recruitingNING LI-GYNJul 8, 2026
A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World SettingMirvetuximab soravtansine—Not yet recruitingAbbVieJul 7, 2026
Tisotumab Vedotin in Squamous Cell Carcinoma of the VulvaTisotumab vedotinPhase 2Not yet recruitingGOG FoundationJun 29, 2026
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerTrastuzumab emtansinePhase 3RecruitingGeneQuantum Healthcare (Suzhou) Co., Ltd.Jun 29, 2026
Optimal Application Timing of ADC Drugs for Advanced Breast CancerEribulin, VinorelbinePhase 2RecruitingLiaoning Cancer Hospital & InstituteJun 18, 2026
Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple MyelomaBelantamab mafodotin—Not yet recruitingPETHEMA FoundationJun 9, 2026
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in SpainBrentuximab vedotin—RecruitingGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaJun 3, 2026
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple MyelomaBelantamab mafodotinPhase 1 / Phase 2Not yet recruitingCentre Hospitalier Universitaire de Saint EtienneMay 29, 2026
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaBelantamab mafodotinPhase 2Not yet recruitingGlaxoSmithKlineMay 29, 2026
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)CabazitaxelPhase 3RecruitingAstraZenecaMay 28, 2026
Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer OrganoidsTrastuzumab emtansine—RecruitingGuangzhou Institute of Respiratory DiseaseMay 28, 2026
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentBelantamab mafodotinPhase 1Not yet recruitingGlaxoSmithKlineMay 27, 2026
Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast CancerVinorelbineNot applicableNot yet recruitingTianjin Medical University Cancer Institute and HospitalMay 15, 2026
GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World SettingTrastuzumab emtansine—RecruitingFondazione OncotechMay 13, 2026
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisTrastuzumab emtansinePhase 3RecruitingSWOG Cancer Research NetworkMay 11, 2026
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaBrentuximab vedotinPhase 2 / Phase 3Not yet recruitingNational Cancer Institute (NCI)May 7, 2026
Extracellular Vesicles and Chemotherapy-Induced Peripheral NeuropathyEribulinNot applicableRecruitingFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoApr 30, 2026
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast CancerEribulin, VinorelbinePhase 3Not yet recruitingMabwell (Shanghai) Bioscience Co., Ltd.Apr 29, 2026
Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLVinblastinePhase 2RecruitingM.D. Anderson Cancer CenterApr 27, 2026
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast CancerEribulin, Vinorelbine—RecruitingFudan UniversityApr 24, 2026
A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant TherapyTrastuzumab emtansine—Not yet recruitingHebei Medical University Fourth HospitalApr 20, 2026
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareEribulinPhase 3RecruitingJiangsu Alphamab Biopharmaceuticals Co., LtdApr 16, 2026
BV-CHP Real-life and Biological Evidences in Patients With sALCLBrentuximab vedotin—Not yet recruitingFondazione Italiana Linfomi - ETSMar 12, 2026
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisVinblastineNot applicableRecruitingWest China Second University HospitalFeb 24, 2026
De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast CancerTrastuzumab emtansinePhase 2Active, not recruitingNational Medical Research Radiological Centre of the Ministry of Health of RussiaFeb 19, 2026
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)VinfluninePhase 3RecruitingMerck Sharp & Dohme LLCFeb 19, 2026
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)PlinabulinPhase 3Not yet recruitingBeyondSpring Pharmaceuticals Inc.Jan 23, 2026
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerTelisotuzumab vedotinPhase 2RecruitingJonsson Comprehensive Cancer CenterJan 7, 2026
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentBrentuximab vedotinPhase 2RecruitingCity of Hope Medical CenterDec 10, 2025
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasBrentuximab vedotinPhase 3Enrolling by invitationN.N. Petrov National Medical Research Center of OncologyDec 2, 2025
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLVinblastinePhase 2RecruitingSt. Petersburg State Pavlov Medical UniversityNov 18, 2025
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerMirvetuximab soravtansinePhase 3RecruitingAstraZenecaOct 20, 2025
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerCabazitaxelPhase 3RecruitingAmgenOct 9, 2025
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerMirvetuximab soravtansinePhase 3RecruitingEli Lilly and CompanyOct 9, 2025
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaVinblastinePhase 2RecruitingNational Research Center for Hematology, RussiaOct 6, 2025
Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before CystectomyVinblastineNot applicableRecruitingAssiut UniversityOct 2, 2025
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant MaintenanceBrentuximab vedotinPhase 3Not yet recruitingAssistance Publique - Hôpitaux de ParisSep 17, 2025
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ LymphomaBrentuximab vedotinPhase 1 / Phase 2RecruitingChinese PLA General HospitalAug 24, 2025
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal CarcinomaPaclitaxel docosahexaenoic acidPhase 2RecruitingAffiliated Hospital of Guangdong Medical UniversityAug 22, 2025
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLVinblastinePhase 2RecruitingNew York Medical CollegeJun 10, 2025
Nivo40-AVD for Advanced Classic Hodgkin LymphomaVinblastinePhase 2RecruitingNational Medical Research Radiological Centre of the Ministry of Health of RussiaMay 22, 2025
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)VinblastinePhase 2RecruitingAstraZenecaMay 7, 2025
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerTisotumab vedotinPhase 4RecruitingPfizerMay 1, 2025
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate CancerCabazitaxelPhase 2Not yet recruitingJina Pharmaceuticals Inc.Mar 24, 2025
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCCabazitaxelPhase 3RecruitingNovartis PharmaceuticalsMar 3, 2025
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate CancerCabazitaxelPhase 2RecruitingCase Comprehensive Cancer CenterDec 17, 2024
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)CabazitaxelPhase 3Active, not recruitingAmgenNov 18, 2024
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialCabazitaxelPhase 2RecruitingAlliance for Clinical Trials in OncologyOct 9, 2024
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Telisotuzumab vedotinPhase 2RecruitingAbbVieAug 23, 2024
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Tisotumab vedotinPhase 3Active, not recruitingMerck Sharp & Dohme LLCJun 14, 2024
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerAnvatabart opadotinPhase 2RecruitingLaura Huppert, MD, BAJan 25, 2024
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCPlinabulinPhase 2RecruitingXiaorong DongFeb 27, 2023
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)PlinabulinPhase 2Active, not recruitingPeking Union Medical College HospitalOct 31, 2022
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)PlinabulinPhase 2Active, not recruitingMemorial Sloan Kettering Cancer CenterNov 23, 2021
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Telisotuzumab vedotinPhase 3RecruitingAbbVieJun 16, 2021
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerAnetumab ravtansinePhase 1Active, not recruitingNational Cancer Institute (NCI)Jan 25, 2019
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerAnetumab ravtansinePhase 2Active, not recruitingNational Cancer Institute (NCI)Jul 16, 2018
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerTelisotuzumab vedotinPhase 2Active, not recruitingAbbVieMay 29, 2018
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsTisotumab vedotinPhase 2Active, not recruitingSeagen, a wholly owned subsidiary of PfizerApr 2, 2018
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerLadiratuzumab vedotinPhase 1 / Phase 2RecruitingHoffmann-La RocheFeb 6, 2018
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsVinfluninePhase 3Active, not recruitingJanssen Research & Development, LLCJan 4, 2018
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural MesotheliomaAnetumab ravtansinePhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Apr 24, 2017
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsTelisotuzumab vedotinPhase 1Active, not recruitingAbbVieMar 28, 2014
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryIxabepilone, PatupilonePhase 1Active, not recruitingNational Cancer Institute (NCI)Jun 17, 2011
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerIxabepilone, PatupilonePhase 2Active, not recruitingNational Cancer Institute (NCI)Sep 15, 2009
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic TherapyIxabepilone, PatupilonePhase 2Active, not recruitingM.D. Anderson Cancer CenterApr 7, 2009

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095182, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.